Interventional Cardiology Devices Market by Type (Stents, Structural Heart Devices, Angioplasty Balloons (Drug-Eluting), Angiography Catheters, Plaque Modification Devices (Thrombectomy Devices), Guidewires, Introducer Sheaths) - Global Forecast to 2029
세계의 IC(Interventional Cardiology) 디바이스 시장 규모는 2024년에 278억 달러에 달하며, 2029년까지 372억 7,000만 달러에 달할 것으로 예측되며, 예측 기간에 CAGR로 6.0%의 성장이 전망됩니다.
| 조사 범위 |
| 조사 대상년 |
2022-2029년 |
| 기준년 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 단위 |
달러 |
| 부문 |
혈관성형 스텐트, 구조적 심질환 디바이스, 카테터, 혈관성형 풍선, 기타 디바이스, 최종사용자, 지역 |
| 대상 지역 |
아시아태평양, 북미, 라틴아메리카, 중동 및 아프리카 |
시장의 성장은 복수의 주요 요인에 의해 촉진되고 있습니다. 특히 전 세계에서 심혈관 질환(CVD) 유병률 증가, 최소침습 수술의 발전, 환자 예후 개선에 대한 수요 증가 등이 주요 요인으로 꼽힙니다. 심장병, 고혈압, 당뇨병의 유병률이 증가함에 따라 혈관 성형술, 스텐트 삽입술, 판막 치환술과 같은 효과적인 치료법에 대한 수요도 증가하고 있습니다. 약제용출성 스텐트, 생체흡수성 스캐폴드, 첨단 영상 기술 개발 등의 기술 혁신으로 보다 안전하고 정확한 수술이 가능해지면서 시장 성장에 기여하고 있습니다.
"혈관형성 풍선 유형별로는 구형/일반형 풍선 부문이 시장에서 가장 높은 CAGR로 성장할 것으로 예상됩니다."
POBA라고도 알려진 기존 혈관 형성 풍선은 특정 임상 시나리오에서 약제용출 풍선(DEB)에 비해 여러 가지 장점이 있습니다. 첫째, 기존 풍선은 DEB보다 비용이 적게 드는 경향이 있으며, 특히 의료 예산이 제한적이거나 환급 정책이 DEB를 완전히 커버할 수 없는 지역에서는 의료 시스템과 환자가 더 쉽게 이용할 수 있는 대안이 될 수 있습니다. 예를 들어 특정 동맥폐색 치료와 같이 약물전달이 치료 결과에 중요하지 않은 급성기에는 POBA가 약제용출의 복잡성이나 비용을 증가시키지 않으면서도 충분한 임상적 결과를 가져올 수 있습니다.
"혈행동태 변화 장비 부문 중 색전증 방지 장비 부문은 시장에서 가장 높은 CAGR로 성장할 것으로 예상됩니다."
색전 방지 장비(EPD)는 중재적 심장학 분야의 중요한 발전으로, 혈관 수술 중 발생할 수 있는 이물질을 포획하고 제거하여 색전증의 위험을 최소화하도록 설계되었습니다. 이 장비는 경동맥 스텐트 삽입술과 같이 이물질이 뇌에 도달하여 뇌졸중을 유발할 수 있는 중재시술에 특히 유용하게 사용될 수 있습니다. 이러한 이물질을 포획함으로써 EPD는 수술 주변의 뇌졸중 위험을 크게 줄여 이러한 수술의 안전성 프로파일을 개선합니다.
"기타 장비 부문의 가이드와이어 부문은 시장에서 가장 높은 CAGR로 성장할 것으로 예상됩니다."
가이드와이어는 혈관 성형술이나 스텐트 삽입술과 같은 수술의 안전성과 유효성을 높이는 정확성, 유연성, 제어력을 제공하는 중재적 심장학에서 필수적인 요소입니다. 이 얇고 유연한 와이어는 카테터를 혈관 내로 유도하여 임상의가 복잡한 혈관 구조를 탐색하고 주변 조직에 대한 외상을 최소화하면서 목표 부위에 도달할 수 있도록 돕습니다. 뛰어난 토크 반응과 조작성을 통해 심장 전문의는 도달하기 어려운 병변에 접근하여 수술 성공률을 높이고 개복 수술의 필요성을 줄일 수 있습니다.
세계의 IC(Interventional Cardiology) 디바이스 시장에 대해 조사분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 제공하고 있습니다.
목차
제1장 서론
제2장 조사 방법
제3장 개요
제4장 주요 인사이트
- IC(Interventional Cardiology) 디바이스 시장의 개요
- 아시아태평양의 IC(Interventional Cardiology) 디바이스 시장 : 최종사용자별
- IC(Interventional Cardiology) 디바이스 시장 : 지역적 성장 기회
- 지역의 구성 : IC(Interventional Cardiology) 디바이스 시장(2022-2029년)
제5장 시장 개요
- 서론
- 시장 역학
- 산업 동향
- 공급망 분석
- 밸류체인 분석
- 기술 분석
- Porter's Five Forces 분석
- 규제 상황
- 가격 분석
- 주요 기업의 평균 판매 가격 : 제품 유형별(2023년)
- IC(Interventional Cardiology) 디바이스의 평균 판매 가격 : 제품 유형별(2023년)
- 평균 판매 가격 : 지역별
- 에코시스템 분석
- 특허 분석
- IC(Interventional Cardiology) 디바이스에 관한 특허 공보의 동향
- 인사이트 : 관할과 상위 출원자 분석
- 무역 분석
- IC(Interventional Cardiology) 디바이스와 소모품 무역 분석
- HS 코드
- 주요 컨퍼런스와 이벤트(2024-2025년)
- 주요 이해관계자와 구입 기준
- 미충족 요구/최종사용자 기대
- IC(Interventional Cardiology) 디바이스 시장에 대한 AI/생성형 AI의 영향
- 사례 연구 분석
- 고객 비즈니스에 영향을 미치는 동향/혼란
- IC(Interventional Cardiology) 디바이스 관련 시장
- 투자와 자금조달 시나리오
제6장 혈관성형 스텐트 시장 : 유형별
- 서론
- 약제용출성 스텐트
- 베어메탈 스텐트
- 생체흡수성 스텐트
제7장 구조적 심질환 디바이스 시장 : 유형별
제8장 카테터 시장 : 유형별
- 서론
- 혈관조영카테터
- 가이드 카테터
- IVUS/OCT 카테터
제9장 혈관성형 풍선 시장 : 유형별
- 서론
- 구형/일반형 풍선
- 약제용출성 풍선
- 커팅/스코어링 풍선
제10장 플라크 제거 디바이스 시장 : 유형별
제11장 혈류조절 디바이스 시장 : 유형별
제12장 기타 IC(Interventional Cardiology) 디바이스 시장 : 유형별
- 서론
- 가이드와이어
- 혈관 폐쇄 디바이스
- 인트로듀서시스
- 풍선 인플레이션 디바이스
- 지혈 심장판막
제13장 IC(Interventional Cardiology) 디바이스 시장 : 최종사용자별
제14장 IC(Interventional Cardiology) 디바이스 시장 : 지역별
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동 및 아프리카
- 중동 및 아프리카의 거시경제 전망
- GCC 국가
- 기타 중동 및 아프리카
제15장 경쟁 구도
- 개요
- 주요 참여 기업의 전략/강점
- 매출 분석
- 시장 점유율 분석
- 기업 평가 매트릭스 : 주요 기업(2023년)
- 기업의 발자국
- 기업 평가 매트릭스 : 스타트업/중소기업(2023년)
- 기업 평가와 재무 지표
- 브랜드/제품 비교 분석
- 주요 기업의 R&D 평가
- 경쟁 시나리오
제16장 기업 개요
- 주요 기업
- BOSTON SCIENTIFIC CORPORATION
- MEDTRONIC
- ABBOTT
- KONINKLIJKE PHILIPS N.V.
- TERUMO CORPORATION
- EDWARDS LIFESCIENCES CORPORATION
- B. BRAUN SE
- INTEGER HOLDINGS CORPORATION
- TELEFLEX INCORPORATED
- PENUMBRA, INC.
- COOK
- CORDIS
- IVASCULAR S.L.U.
- BIOSENSORS INTERNATIONAL GROUP, LTD.
- BIOTRONIK SE & CO. KG
- 기타 기업
- AMG INTERNATIONAL(SUBSIDIARY OF Q3 MEDICAL)
- ENDOCOR GMBH & CO. KG
- INSITU TECHNOLOGIES, INC.
- MERIL LIFE SCIENCES PVT. LTD
- ALVIMEDICA
- CARDIONOVUM GMBH
- MEDINOL
- WELLINQ
- BALTON SP.
- TRANSLUMINA
제17장 부록
KSA
The global interventional cardiology devices market is projected to reach USD 27.80 billion in 2024 and is projected to reach USD 37.27 billion by 2029, at a CAGR of 6.0% during the forecast period.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Angioplasty Stents, Structural Heart Devices, Catheters, Angioplasty Balloons, Other Devices, End user and Region |
| Regions covered | Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. |
The growth of the interventional cardiology devices market is driven by several key factors, most notably the increasing prevalence of cardiovascular diseases (CVD) worldwide, advancements in minimally invasive procedures, and growing demand for improved patient outcomes. As rates of heart disease, hypertension, and diabetes rise, the need for effective treatments such as angioplasty, stenting, and valve replacements also increases. Technological innovations, including the development of drug-eluting stents, bioresorbable scaffolds, and advanced imaging technologies, have enabled safer and more precise procedures, which contribute to the market's growth.
"Based on the angioplasty balloons type, the old/normal balloons segment is expected to grow by the highest CAGR in the interventional cardiology devices market."
Traditional angioplasty balloons, also known as plain old balloon angioplasty (POBA), offer several advantages over drug-eluting balloons (DEBs) in certain clinical scenarios. First, traditional balloons tend to be less costly than DEBs, making them a more accessible option for healthcare systems and patients, especially in regions with limited healthcare budgets or where reimbursement policies may not fully cover DEB, also POBA also has a simpler mechanism-it dilates narrowed blood vessels by compressing plaque against the vessel walls without releasing drugs, which can be beneficial in cases where the risks associated with drug delivery aren't justified. For example, in acute settings like treating certain types of arterial blockages where drug-delivery isn't critical to outcomes, POBA may provide sufficient clinical results without the added complexity or cost of drug elution.
"The embolic protection devices segment in hemodynamic flow alteration devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market."
Embolic protection devices (EPDs) are a vital advancement in interventional cardiology, designed to capture and remove debris that may dislodge during vascular procedures, thereby minimizing the risk of embolization. These devices are particularly beneficial during interventions like carotid artery stenting, where dislodged particles could travel to the brain and cause strokes. By capturing such debris, EPDs significantly reduce periprocedural stroke risks and improve the safety profile of these interventions.
"The guidewires segment in other devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market."
Guidewires are essential in interventional cardiology, offering precision, flexibility, and control that enhance the safety and effectiveness of procedures like angioplasty and stent placement. These thin, flexible wires guide catheters through blood vessels, allowing clinicians to navigate complex vascular structures and reach targeted areas with minimal trauma to surrounding tissues. Their superior torque response and maneuverability help cardiologists access difficult-to-reach lesions, improving procedural success rates and reducing the need for open surgery.
"Based on the end user, hospitals segment is expected to grow by the highest CAGR in the interventional cardiology devices market.
Most interventional cardiology procedures, such as angioplasties, stent placements, and structural heart interventions, are carried out in hospitals because they boast special facilities and the sophisticated imaging technologies that would treat a patient with maximum quality. They are well equipped both for simple and complicated processes with a good staff; besides, they are where they can be managed whenever a complication arises. These settings enable cardiologists to take the latest tool systems into practice, including drug-eluting stents, rotational atherectomy and intravascular ultrasound, to ensure utmost precision and safety for patients.
"Asia Pacific to grow with the highest CAGR in the interventional cardiology devices market during the forecast period."
The Asia-Pacific region is also expected to experience maximum growth in the interventional cardiology devices market in the next few years due to several key factors. Growth is driven by an increasingly aging population, the growing prevalence of cardiovascular diseases, and increased adoption of minimally invasive procedures, especially in countries such as China, Japan, and India. Increased healthcare expenses and development of health infrastructure promote the availability of high-end interventional cardiology services throughout the region.
The break up of the profile of primary participants in the interventional cardiology devices market:
- By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
- By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
- By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%,Middle East & Africa-5%
Key players in the interventional cardiology devices market
Some of the prominent players operating in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), BIOTRONIK SE & Co. KG (Germany), AMG International (Germany), ENDOCOR GmbH (Germany), InSitu Technologies, Inc. (US), Meril Life Sciences (India), Alvimedica (Istanbul), Cardionovum GmBH (Germany), Medinol Ltd (Turkey), Wellinq (Netherlands), Balton SP (Poland), Translumina (India).
Research Coverage:
The report analyzes the interventional cardiology devices market and aims at estimating the market size and future growth potential of this market based on various segments such as angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user. The report also includes a product portfolio matrix of various interventional cardiology technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall interventional cardiology devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
- Of Analysis of key drivers (growing prevalence of cardiovascular diseases, technological advancements in interventional cardiology procedures, increased prevalence of diabetes & growing product launches by leading players in developing countries), restraints (availability of alternative treatments & recall of products by industry participants to limit the uptake of interventional cardiology equipment), opportunities (high growth potential in emerging markets & growing coronary stent demand in developing countries) and challenges (stringent regulatory requirements delaying the approval of cardiac devices).
- Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global interventional cardiology devices market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global interventional cardiology devices market
- Market Development: Comprehensive information on the lucrative emerging markets by angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user.
- Market Diversification: Exhaustive information about new product and services or product and service enhancements, growing geographies, recent developments, and investments in the global interventional cardiology devices market.
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of product and services, and capacities of the major competitors in the global interventional cardiology devices market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKET SEGMENTATION
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 MARKET STAKEHOLDERS
- 1.5 LIMITATIONS
- 1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 INTRODUCTION
- 2.1.1 SECONDARY RESEARCH
- 2.1.2 KEY DATA FROM SECONDARY SOURCES
- 2.1.3 KEY DATA FROM PRIMARY SOURCES
- 2.1.3.1 Insights from primary experts
- 2.2 MARKET SIZE ESTIMATION
- 2.3 DATA TRIANGULATION APPROACH
- 2.4 MARKET SHARE ANALYSIS
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.6.1 METHODOLOGY-RELATED LIMITATIONS
- 2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET OVERVIEW
- 4.2 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER
- 4.3 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.4 REGIONAL MIX: INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2022-2029)
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing prevalence of cardiovascular diseases
- 5.2.1.2 Rising technological investments in interventional cardiology procedures
- 5.2.1.3 Increasing prevalence of diabetes
- 5.2.1.4 Favorable regulatory support
- 5.2.2 RESTRAINTS
- 5.2.2.1 Availability of alternative treatments
- 5.2.2.2 Product recalls
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 High growth potential in emerging markets
- 5.2.3.2 Increasing demand for coronary stents
- 5.2.4 CHALLENGES
- 5.2.4.1 Stringent regulatory requirements for product approvals
- 5.3 INDUSTRY TRENDS
- 5.3.1 DRUG-ELUTING TECHNOLOGIES
- 5.3.2 INCREASING EMPHASIS ON MINIMALLY INVASIVE PROCEDURES
- 5.4 SUPPLY CHAIN ANALYSIS
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 TECHNOLOGY ANALYSIS
- 5.6.1 KEY TECHNOLOGIES
- 5.6.2 ADJACENT TECHNOLOGIES
- 5.6.3 COMPLEMENTARY TECHNOLOGIES
- 5.6.3.1 Integration of real-time monitoring into wearable technologies
- 5.6.3.2 Precise cardiovascular interventions through artificial intelligence
- 5.7 PORTER'S FIVE FORCES ANALYSIS
- 5.7.1 THREAT OF NEW ENTRANTS
- 5.7.2 THREAT OF SUBSTITUTES
- 5.7.3 BARGAINING POWER OF SUPPLIERS
- 5.7.4 BARGAINING POWER OF BUYERS
- 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.8 REGULATORY LANDSCAPE
- 5.8.1 REGULATORY ANALYSIS
- 5.8.1.1 North America
- 5.8.1.2 Europe
- 5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.9 PRICING ANALYSIS
- 5.9.1 INDICATIVE AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT TYPE, 2023
- 5.9.2 INDICATIVE AVERAGE SELLING PRICE OF INTERVENTIONAL CARDIOLOGY DEVICES, BY PRODUCT TYPE, 2023
- 5.9.3 INDICATIVE AVERAGE SELLING PRICE, BY REGION
- 5.10 ECOSYSTEM ANALYSIS
- 5.11 PATENT ANALYSIS
- 5.11.1 PATENT PUBLICATION TRENDS FOR INTERVENTIONAL CARDIOLOGY DEVICES
- 5.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.12 TRADE ANALYSIS
- 5.12.1 TRADE ANALYSIS FOR INTERVENTIONAL CARDIOLOGY DEVICES AND CONSUMABLES
- 5.12.2 HS CODES
- 5.13 KEY CONFERENCES & EVENTS, 2024-2025
- 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 BUYING CRITERIA
- 5.15 UNMET NEEDS/END-USER EXPECTATIONS
- 5.16 IMPACT OF AI/GEN AI ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET
- 5.17 CASE STUDY ANALYSIS
- 5.17.1 CASE STUDY 1: BOSTON SCIENTIFIC CORPORATION USES GUIDEZILLA II EXTENSION CATHETER FOR PC INTERVENTIONS
- 5.17.2 CASE STUDY 2: MEDTRONIC PROVIDES CARDIOLOGY DEVICES FOR VENOUS INTERVENTIONS
- 5.17.3 CASE STUDY 3: ABOTT OFFERS DRUG-ELUTING STENTS FOR PATIENTS WITH HIGHER RISK OF STROKE
- 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.19 ADJACENT MARKETS FOR INTERVENTIONAL CARDIOLOGY DEVICES
- 5.20 INVESTMENT & FUNDING SCENARIO
6 ANGIOPLASTY STENTS MARKET, BY TYPE
- 6.1 INTRODUCTION
- 6.1.1 DRUG-ELUTING STENTS
- 6.1.1.1 Drug-eluting stents to hold largest share of angioplasty stents market
- 6.1.2 BARE-METAL STENTS
- 6.1.2.1 Increasing use of drug-eluting stents to limit growth of bare-metal stents market
- 6.1.3 BIOABSORBABLE STENTS
- 6.1.3.1 Ability of bioabsorbable stents to ensure complete healing of arteries to propel demand
7 STRUCTURAL HEART DEVICES MARKET, BY TYPE
- 7.1 INTRODUCTION
- 7.1.1 AORTIC VALVE THERAPY DEVICES
- 7.1.1.1 Increasing prevalence of aortic valve stenosis to support market growth
- 7.1.2 OTHER THERAPY DEVICES
8 CATHETERS MARKET, BY TYPE
- 8.1 INTRODUCTION
- 8.1.1 ANGIOGRAPHY CATHETERS
- 8.1.1.1 Rising cases of artery disease and heart attacks to propel market
- 8.1.2 GUIDING CATHETERS
- 8.1.2.1 Increasing number of angiography procedures to drive the market
- 8.1.3 IVUS/OCT CATHETERS
- 8.1.3.1 Ability to obtain 3D images for aneurysm assessment to support market growth
9 ANGIOPLASTY BALLOONS MARKET, BY TYPE
- 9.1 INTRODUCTION
- 9.1.1 OLD/NORMAL BALLOONS
- 9.1.1.1 Low treatment costs associated with old/normal balloons to drive growth
- 9.1.2 DRUG-ELUTING BALLOONS
- 9.1.2.1 Rising number of regulatory approvals for drug-eluting balloons to support market growth during forecast period
- 9.1.3 CUTTING/SCORING BALLOONS
- 9.1.3.1 Limited use of cutting balloon-aided procedures to restrain market growth
10 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE
- 10.1 INTRODUCTION
- 10.1.1 THROMBECTOMY DEVICES
- 10.1.1.1 Ability to remove blood clots in STEMI and NSTEMI patients to propel market
- 10.1.2 ATHERECTOMY DEVICES
- 10.1.2.1 Increasing use of lipid-modifying drugs for atherosclerosis to support market growth
11 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE
- 11.1 INTRODUCTION
- 11.1.1 EMBOLIC PROTECTION DEVICES
- 11.1.1.1 Adoption of filter & occlusion-based devices to propel market
- 11.1.2 CHRONIC TOTAL OCCLUSION DEVICES
- 11.1.2.1 Uptake in treatment of total occlusions to drive market
12 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE
- 12.1 INTRODUCTION
- 12.1.1 GUIDEWIRES
- 12.1.1.1 Growing demand for stent placements and coronary intervention procedures to propel market
- 12.1.2 VASCULAR CLOSURE DEVICES
- 12.1.2.1 Ability to provide increased efficacy in patient outcomes to fuel uptake
- 12.1.3 INTRODUCER SHEATHS
- 12.1.3.1 Ability to provide secure access to blood vessels to support market growth
- 12.1.4 BALLOON INFLATION DEVICES
- 12.1.4.1 Increasing incidence of peripheral artery disease to drive market
- 12.1.5 HEMOSTASIS HEART VALVES
- 12.1.5.1 Growing focus on precision medicine
13 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER
- 13.1 INTRODUCTION
- 13.2 HOSPITALS
- 13.2.1 AVAILABILITY OF ADVANCED INFRASTRUCTURE AND SPECIALIZED EQUIPMENT TO DRIVE MARKET
- 13.3 AMBULATORY SURGERY CENTERS
- 13.3.1 LOW CASES OF HAIS AND SHORTER RECOVERY TIMES TO PROPEL MARKET
- 13.4 OTHER END USERS
14 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION
- 14.1 INTRODUCTION
- 14.2 NORTH AMERICA
- 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 14.2.2 US
- 14.2.2.1 Availability of reimbursements for cardiology procedures to drive market
- 14.2.3 CANADA
- 14.2.3.1 Rising prevalence of chronic diseases to drive market
- 14.3 EUROPE
- 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 14.3.2 GERMANY
- 14.3.2.1 Growing hub for advanced technology product distributors to drive market
- 14.3.3 FRANCE
- 14.3.3.1 Favorable government initiatives in France to support market growth
- 14.3.4 UK
- 14.3.4.1 Growing focus on personalized medicine to fuel uptake
- 14.3.5 ITALY
- 14.3.5.1 Increasing cases of obesity and CVD to support market growth
- 14.3.6 SPAIN
- 14.3.6.1 Increasing prevalence of age-related CVD conditions to drive market
- 14.3.7 REST OF EUROPE
- 14.4 ASIA PACIFIC
- 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 14.4.2 CHINA
- 14.4.2.1 High tobacco consumption and increasing cases of CVD to fuel uptake
- 14.4.3 JAPAN
- 14.4.3.1 Increasing demand for stents and catheters to support market growth
- 14.4.4 INDIA
- 14.4.4.1 Improvements in angioplasty devices to fuel uptake
- 14.4.5 AUSTRALIA
- 14.4.5.1 Increasing cases of lifestyle disorders to support market growth
- 14.4.6 SOUTH KOREA
- 14.4.6.1 Growth in pharmaceutical sectors to propel market
- 14.4.7 REST OF ASIA PACIFIC
- 14.5 LATIN AMERICA
- 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 14.5.2 BRAZIL
- 14.5.2.1 Rising demand for quality treatment and focus on growing healthcare infrastructure to drive market
- 14.5.3 MEXICO
- 14.5.3.1 Increasing cases of diabetes to fuel market
- 14.5.4 REST OF LATIN AMERICA
- 14.6 MIDDLE EAST & AFRICA
- 14.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
- 14.6.2 GCC COUNTRIES
- 14.6.3 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
- 15.1 OVERVIEW
- 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET
- 15.3 REVENUE ANALYSIS
- 15.4 MARKET SHARE ANALYSIS
- 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 15.5.1 STARS
- 15.5.2 EMERGING LEADERS
- 15.5.3 PERVASIVE PLAYERS
- 15.5.4 PARTICIPANTS
- 15.6 COMPANY FOOTPRINT
- 15.6.1 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 15.6.1.1 Company footprint
- 15.6.1.2 Region footprint
- 15.6.1.3 Product footprint
- 15.6.1.4 Angioplasty stents footprint
- 15.6.1.5 Structural heart devices footprint
- 15.6.1.6 Catheters footprint
- 15.6.1.7 Angioplasty balloons footprint
- 15.6.1.8 Plaque modification devices footprint
- 15.6.1.9 Hemodynamic flow alteration devices footprint
- 15.6.1.10 Other interventional cardiology devices footprint
- 15.6.1.11 End-user footprint
- 15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 15.7.1 PROGRESSIVE COMPANIES
- 15.7.2 RESPONSIVE COMPANIES
- 15.7.3 DYNAMIC COMPANIES
- 15.7.4 STARTING BLOCKS
- 15.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 15.8 COMPANY VALUATION & FINANCIAL METRICS
- 15.8.1 FINANCIAL METRICS
- 15.8.2 COMPANY VALUATION
- 15.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
- 15.10 R&D ASSESSMENT OF KEY PLAYERS
- 15.11 COMPETITIVE SCENARIO
- 15.11.1 PRODUCT LAUNCHES & APPROVALS
- 15.11.2 DEALS
- 15.11.3 EXPANSIONS
16 COMPANY PROFILES
- 16.1 KEY PLAYERS
- 16.1.1 BOSTON SCIENTIFIC CORPORATION
- 16.1.1.1 Business overview
- 16.1.1.2 Products offered
- 16.1.1.3 Recent developments
- 16.1.1.3.1 Product launches & approvals
- 16.1.1.3.2 Deals
- 16.1.1.4 MnM view
- 16.1.1.4.1 Key strengths
- 16.1.1.4.2 Strategic choices
- 16.1.1.4.3 Weaknesses & competitive threats
- 16.1.2 MEDTRONIC
- 16.1.2.1 Business overview
- 16.1.2.2 Products offered
- 16.1.2.3 Recent developments
- 16.1.2.3.1 Product launches & approvals
- 16.1.2.3.2 Deals
- 16.1.2.4 MnM view
- 16.1.2.4.1 Key strengths
- 16.1.2.4.2 Strategic choices
- 16.1.2.4.3 Weaknesses & competitive threats
- 16.1.3 ABBOTT
- 16.1.3.1 Business overview
- 16.1.3.2 Products offered
- 16.1.3.3 Recent developments
- 16.1.3.3.1 Product launches & approvals
- 16.1.3.3.2 Deals
- 16.1.3.4 MnM view
- 16.1.3.4.1 Key strengths
- 16.1.3.4.2 Strategic choices
- 16.1.3.4.3 Weaknesses & competitive threats
- 16.1.4 KONINKLIJKE PHILIPS N.V.
- 16.1.4.1 Business overview
- 16.1.4.2 Products offered
- 16.1.4.3 Recent developments
- 16.1.5 TERUMO CORPORATION
- 16.1.5.1 Business overview
- 16.1.5.2 Products offered
- 16.1.5.3 Recent developments
- 16.1.5.3.1 Product launches
- 16.1.5.3.2 Expansions
- 16.1.5.4 MnM view
- 16.1.5.4.1 Key strengths
- 16.1.5.4.2 Strategic choices
- 16.1.5.4.3 Weaknesses & competitive threats
- 16.1.6 EDWARDS LIFESCIENCES CORPORATION
- 16.1.6.1 Business overview
- 16.1.6.2 Products offered
- 16.1.6.3 Recent developments
- 16.1.6.3.1 Product launches & approvals
- 16.1.6.3.2 Deals
- 16.1.7 B. BRAUN SE
- 16.1.7.1 Business overview
- 16.1.7.2 Products offered
- 16.1.7.3 Recent developments
- 16.1.7.3.1 Product launches & approvals
- 16.1.7.3.2 Deals
- 16.1.8 INTEGER HOLDINGS CORPORATION
- 16.1.8.1 Business overview
- 16.1.8.2 Products offered
- 16.1.8.3 Recent developments
- 16.1.8.3.1 Deals
- 16.1.8.3.2 Expansions
- 16.1.9 TELEFLEX INCORPORATED
- 16.1.9.1 Business overview
- 16.1.9.2 Products offered
- 16.1.9.3 Recent developments
- 16.1.9.3.1 Product approvals
- 16.1.10 PENUMBRA, INC.
- 16.1.10.1 Business overview
- 16.1.10.2 Products offered
- 16.1.10.3 Recent developments
- 16.1.10.3.1 Product launches & approvals
- 16.1.11 COOK
- 16.1.11.1 Business overview
- 16.1.11.2 Products offered
- 16.1.11.3 Recent developments
- 16.1.12 CORDIS
- 16.1.12.1 Business overview
- 16.1.12.2 Products offered
- 16.1.12.3 Recent developments
- 16.1.12.3.1 Product launches & approvals
- 16.1.12.3.2 Deals
- 16.1.13 IVASCULAR S.L.U.
- 16.1.13.1 Business overview
- 16.1.13.2 Products offered
- 16.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD.
- 16.1.14.1 Business overview
- 16.1.14.2 Products offered
- 16.1.14.3 Recent developments
- 16.1.14.3.1 Product launches
- 16.1.15 BIOTRONIK SE & CO. KG
- 16.1.15.1 Business overview
- 16.1.15.2 Products offered
- 16.1.15.3 Recent developments
- 16.1.15.3.1 Product launches
- 16.2 OTHER PLAYERS
- 16.2.1 AMG INTERNATIONAL (SUBSIDIARY OF Q3 MEDICAL)
- 16.2.2 ENDOCOR GMBH & CO. KG
- 16.2.3 INSITU TECHNOLOGIES, INC.
- 16.2.4 MERIL LIFE SCIENCES PVT. LTD
- 16.2.5 ALVIMEDICA
- 16.2.6 CARDIONOVUM GMBH
- 16.2.7 MEDINOL
- 16.2.8 WELLINQ
- 16.2.9 BALTON SP.
- 16.2.10 TRANSLUMINA
17 APPENDIX
- 17.1 DISCUSSION GUIDE
- 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 17.3 CUSTOMIZATION OPTIONS
- 17.4 RELATED REPORTS
- 17.5 AUTHOR DETAILS
